Table. Baseline Characteristics Associated With eGFR Levels at Randomizationa.
| Characteristic | Baseline eGFR, mL/min/1.73 m2 | P value | ||
|---|---|---|---|---|
| eGFR ≥90 (n = 2722) | eGFR 60-90 (n = 8578) | eGFR <60 (n = 3311) | ||
| Demographics and risk factors | ||||
| Age, y, median (IQR) | 57.0 (51-62) | 65.0 (60-71) | 71.0 (66-76) | <.001 |
| Female, No. (%) | 389 (14.3) | 1470 (17.1) | 841 (25.4) | <.001 |
| Male, No. (%) | 2333 (85.7) | 7108 (82.9) | 2470 (74.6) | <.001 |
| BMI, median (IQR) | 28.4 (25-32) | 28.4 (26-32) | 28.4 (26-32) | .09 |
| Current smoker, No. (%) | 884 (32.5) | 1480 (17.3) | 289 (8.7) | <.001 |
| Geographic region, No. (%) | ||||
| Asia/Pacific | 639 (23.5) | 1441 (16.8) | 501 (15.1) | <.001 |
| Eastern Europe | 673 (24.7) | 2123 (24.7) | 654 (19.8) | |
| North America | 516 (19.0) | 2205 (25.7) | 1118 (33.8) | |
| South America | 135 (5.0) | 509 (5.9) | 231 (7.0) | |
| Western Europe | 759 (27.9) | 2300 (26.8) | 807 (24.4) | |
| Medical history, No. (%) | ||||
| Hypertension | 1781 (65.4) | 6057 (70.6) | 2614 (78.9) | <.001 |
| Diabetes | 1144 (42.0) | 3097 (36.1) | 1410 (42.6) | <.001 |
| Multivessel CHD | 333 (12.2) | 1222 (14.2) | 519 (15.7) | .001 |
| Prior MI | 1753 (64.4) | 5093 (59.4) | 1805 (54.5) | <.001 |
| Prior PCI or CABG | 1958 (71.9) | 6407 (74.7) | 2529 (76.4) | <.001 |
| Polyvascular disease | 335 (12.3) | 1241 (14.5) | 649 (19.6) | <.001 |
| Biochemical analyses, median (IQR) | ||||
| hs-IL-6, ng/L | 1.9 (1-3) | 2.0 (1-3) | 2.5 (2-4) | <.001 |
| hs-CRP, mg/dL | 0.14 (0.10-0.30) | 0.13 (0.10-0.30) | 0.16 (0.10-0.40) | <.001 |
| No. (total n = 13 907) | 2600 | 8165 | 3142 | NA |
| White blood cell count, /µL | 6800 (6000-8000) | 6500 (6000-8000) | 6600 (6000-8000) | <.001 |
| No. (total n = 14 145) | 2642 | 8297 | 3206 | NA |
| Hemoglobin, g/dL | 14.6 (13.8-15.3) | 14.5 (13.6-15.3) | 13.8 (12.8-14.8) | <.001 |
| No. (total n = 14 162) | 2645 | 8306 | 3211 | NA |
| Cystatin C, ng/L | 0.8 (1-1) | 1.0 (1-1) | 1.3 (1-2) | <.001 |
| No. (total n = 14 376) | 2678 | 8441 | 3257 | NA |
| Lp-PLA2 activity, μmol/min/L | 173.5 (143-206) | 172.3 (143-203) | 171.9 (143-206) | <.001 |
| No. (total n = 14 349) | 2671 | 8424 | 3254 | NA |
| hs-Troponin T, ng/mL | 0.007 (0.005-0.010) | 0.009 (0.006-0.013) | 0.014 (0.009-0.020) | <.001 |
| No. (total n = 14 331) | 2670 | 8416 | 3245 | NA |
| NT-proBNP, ng/L | 109.0 (54-229) | 161.0 (81-334) | 303.0 (148-679) | <.001 |
| No. (total n = 14 366) | 2677 | 8432 | 3257 | NA |
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CABG, coronary artery bypass graft surgery; CHD, coronary heart disease; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; hs, high-sensitivity; IL-6, interleukin 6; IQR, interquartile range; Lp-PLA2, lipoprotein-associated phospholipase A2; MI, myocardial infarction; NA, not applicable; NT-proBNP, N-terminal pro–B-type natriuretic peptide; PCI, percutaneous coronary intervention.
SI conversion factors: To convert CRP to mg/L, multiply by 10; hemoglobin to g/L, multiply by 10; troponin T to µg/L, multiply by 1; white blood cell count to ×109/L, multiply by 0.001.
eGFR levels are based on the Chronic Kidney Disease Epidemiology Collaboration equation.